AMBU B Ambu A/S Class B

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees. 

The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT margin) for the fiscal year 2023/24 and will be within the range of 0-200% of the initial grant. 

The PSUs are granted free and subject to achievement of the KPIs mentioned above. Each PSU will at vesting, on 1 January 2027, be converted to one Class B share in Ambu A/S subject to the terms of the LTIP. 

The average price applied to calculate the number of PSUs is the average price quoted by NASDAQ Copenhagen in respect of Ambu A/S Class B shares on the day of the Annual General Meeting and the subsequent four (4) trading days (13-19 December 2023). 

The value of the PSUs will, at the time of vesting, be capped at four times the annual base salary of the individual participant measured at the time of the grant. 





Ambu A/S

Baltorpbakken 13 2750 Ballerup 

Denmark

Tel.  

CVR no.: 63 64 49 19





CONTACT

Investors 

Anders Hjort 

Head of Investor Relations

 





Media 

Tine Bjørn Schmidt

Head of Corporate Communications







ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit .

Attachment



EN
06/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 2 directors

Two Directors at Ambu AS bought 21,500 shares at between 112.950DKK and 114.090DKK. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK140.00) - Solid guidance considering soft Q4

We view the 2024/25 guidance as solid given the Q4 miss and management’s conservative tendency. Pulmonology growth might be below our forecast for 2024/25, but the strong momentum in the rest of Endoscopy should make up for it. We view the investment case as intact, and thus reiterate our BUY, but have cut our target price to DKK140 (145) on the Q4 margin miss.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK145.00) - Q4 focus: Pulmonary and guidance

We believe Ambu will report a stronger Q4 than expected by consensus, but ultimately expect focus to be on the Pulmonary growth momentum in the quarter as well as the 2024/25 guidance. We look for guidance of at least 10–13% organic growth, with consensus at the high end, but which we view as probably conservative. We reiterate our BUY and DKK145 target price.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch